retatrutide blindness Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 STUDY: Novel “Triagonist” Retatrutide Resolved

The drug significantly slowed biological processes associated with the risk of allcause mortality and age-related disease, as measured by the PCGrimAge epigenetic clock

At 68 weeks, the treatment-regimen estimand results were -20.0% (9 mg dose, approximately 50.5 pounds) and -23.7% (12 mg dose, approximately 60 pounds)

Recommended dosage is 2.5mg for the first 4 weeks, then 5mg for the next 4 weeks

Orlistat is currently the only FDA-approved lipase inhibitor for weight loss

Phase 2 clinical trial data published in 2023 in the New England Journal of Medicine (Jastreboff et al., NEJM 2023) demonstrated substantial weight reduction in participants with obesity

2026 Feb 25